Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710279 | 0.83 | GAA (0.43) | MAPTGAA | |
| SCHEMBL4903371 | 0.83 | GAA (0.41) | MAPTGAAKCNH2ALDH1A1 | |
| SCHEMBL8900868 | 0.82 | GAA (0.38) | MAPTGAASLC6A4ADRA1ASLC6A3 | |
| SCHEMBL28100450 | 0.81 | GAA (0.40) | MAPTGAAKCNH2ALDH1A1 | |
| SCHEMBL27943725 | 0.81 | GAA (0.40) | MAPTGAAKCNH2ALDH1A1 | |
| Hydrazine SCHEMBL28113327 | 0.79 | GAA (0.38) | MAPTGAAHTR2AKCNH2ALDH1A1 | |
| SCHEMBL27682149 | 0.79 | GAA (0.44) | MAPTGAAHTR2AKCNH2ALDH1A1 | |
| SCHEMBL8642184 | 0.78 | KEAP1 (0.41) | MAPTGAACHRM1ADRA1ASLC6A3 | |
| SCHEMBL8696697 | 0.76 | GAA (0.43) | MAPTGAAHTR2A | |
| SCHEMBL9934042 | 0.76 | GAA (0.43) | MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | claimed |
| EP-1594879-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-10-22 | — | — | EP | claimed |
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL D.D. (SI) | 2006-02-23 | — | — | US | claimed |
| EP-1594879-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2005-11-16 | — | — | EP | claimed |
| WO-2004065390-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2004-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | CYP4F11, CYP4A11, CYP3A4 | MAPT 1845/4885GAA 1434/4885CHRM2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.